AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap to about $3.45 billion. CFO Booth Andrew showed insider confidence by purchasing 37,200 shares at $10.32 each, increasing his holdings. The drug was well-tolerated with no serious side effects, and the company recently raised $200 million through an oversubscribed public offering, signaling strong investor interest and potential growth ahead.